1. Scrip
  2. >>Focus On Asia

Japan Results Roundup: Global Mainstays And Forex Boost Top Lines

 
• By Lisa Takagi

Mostly strong global sales of mainstay drugs, along with a forex boost, helped Japan's major pharma firms in the fiscal third quarter and calendar year.

Japan's Q4 results
(Shutterstock)

Along with generally strong mainstay sales, the continued weakening of the yen boosted overseas sales at major Japanese pharma firms in the fiscal third quarter and full year ended 31 December. The Japanese currency was hovering around JPY148 to the US dollar in February 2024 but has fallen to around JPY153 this February.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By Vibha Ravi

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.